Get the Stockscreener App
1.76
3.53%
+0.06
After Hours:
1.76
Ocean Biomedical Inc. stock is currently priced at $1.76, with a 24-hour trading volume of 144.93K.
It has seen a +3.53% increased in the last 24 hours and a -1.40% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.68 pivot point. If it approaches the $1.78 resistance level, significant changes may occur.
Previous Close:
$1.70
Open:
$1.73
24h Volume:
144.93K
Market Cap:
$60.98M
Revenue:
-
Net Income/Loss:
$-77.50M
P/E Ratio:
-0.4585
EPS:
-3.839
Net Cash Flow:
$-8.35M
1W Performance:
+14.66%
1M Performance:
-1.40%
6M Performance:
+62.96%
1Y Performance:
-65.69%
1D Range:
$1.6513
$1.78
52W Range:
$0.52
$12.08
Ocean Biomedical Inc. Stock (OCEA) Company Profile
Name
Ocean Biomedical Inc.
Sector
Industry
Phone
401-444-7375
Address
Room 325, 55 Claverick Street, Providence
Ocean Biomedical Inc. Stock (OCEA) Latest News
Ocean Biomedical Inc.’s Shares Reel: 189.95% Quarterly Revenue Decline Amid 60.29M Market Cap - The InvestChronicle
The InvestChronicle
Market Insight: Ocean Biomedical Inc. (OCEA)'s Notable Gain, Closing at 1.74 – DWinneX - The Dwinnex
The Dwinnex
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - Markets Insider
Markets Insider
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - BioSpace
BioSpace
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease - ForexTV.com
ForexTV.com
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential ... - GlobeNewswire
GlobeNewswire
Ocean Biomedical Inc. Stock (OCEA) Financials Data
Ocean Biomedical Inc. (OCEA) Net Income 2024
OCEA net income (TTM) was -$77.50 million for the quarter ending September 30, 2023, a -264.51% decrease year-over-year.
Ocean Biomedical Inc. (OCEA) Cash Flow 2024
OCEA recorded a free cash flow (TTM) of -$8.35 million for the quarter ending September 30, 2023, a -657.74% decrease year-over-year.
Ocean Biomedical Inc. (OCEA) Earnings per Share 2024
OCEA earnings per share (TTM) was -$2.9169 for the quarter ending September 30, 2023, a -177.17% decline year-over-year.
About Ocean Biomedical Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
0.77%
1.20%
Cap:
|
Volume (24h):